CARCINOMA, NON-SMALL-CELL LUNG

This early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…

This study tested whether adding another drug to the immunotherapy pembrolizumab (Keytruda) can help people with advanced non-small cell lung cancer whose disease got worse after initial treatment. 128 participants received one of three drug combinations. The goal was to see if t…

This phase 3 trial tested the immunotherapy drug cemiplimab against standard platinum-based chemotherapy in 712 patients with advanced or metastatic non-small cell lung cancer that has high PD-L1 levels. The study aimed to see if cemiplimab improves overall survival and delays ca…

This study reviews medical records of 35 adults with a specific lung cancer (ROS1-positive NSCLC) that had not been controlled by other treatments. All participants took lorlatinib pills at home until their cancer stopped responding. Researchers will analyze how long the drug kep…

This completed Phase 1/2 trial tested a combination of two drugs, amivantamab and docetaxel, in 12 people with advanced non-small cell lung cancer that had spread. The goal was to find a safe dose and see if the combo could shrink tumors. The study focused on patients whose cance…

This study tracked 296 patients with advanced or recurrent non-small cell lung cancer who received a combination of IMJUDO, IMFINZI, and platinum-based chemotherapy. The goal was to see how safe the treatment is in everyday medical practice. Researchers recorded any side effects …

This study tested a combination of two drugs, SHR-1210 (given through a vein) and Apatinib (a daily pill), in 210 adults with advanced non-small cell lung cancer that had stopped responding to standard chemotherapy. The goal was to see if the combo could shrink tumors and to chec…

This study tested a combination of two drugs—bevacizumab and a higher dose of icotinib—in 35 people with advanced non-squamous lung cancer that has a specific genetic change (EGFR L858R). The goal was to see if this combo could delay cancer growth better than standard treatment. …

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This study tested whether adding a new drug (LY2875358) to the standard treatment erlotinib helps people with advanced non-small cell lung cancer that has a specific gene mutation. All 168 participants first took erlotinib alone for 8 weeks. Those whose cancer did not worsen were…

This study tested a drug called cabozantinib, either alone or with another drug (erlotinib), in 92 people with advanced non-small cell lung cancer whose cancer had worsened after erlotinib treatment. The goal was to find a safe dose and see if the combination could shrink tumors.…

This study tested a combination of two targeted drugs, dabrafenib and trametinib, in 40 Chinese adults with a specific type of advanced lung cancer (BRAF V600E mutation-positive NSCLC). The goal was to see if the drugs could shrink tumors and control the cancer. Participants rece…

This phase 2 trial tested a combination of the immunotherapy drug durvalumab with two chemotherapy drugs (doxorubicin and ifosfamide) in 16 people with a rare and aggressive type of lung cancer called pulmonary sarcomatoid carcinoma. The goal was to see if the combination could s…

This study tested whether combining the immunotherapy atezolizumab (Tecentriq) with the targeted drug cabozantinib works better than the standard chemotherapy docetaxel for people with advanced non-small cell lung cancer that has worsened after prior treatment. The trial enrolled…

This early-stage trial tested the safety of a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, stomach cancers). The main goal was to identify side effects and see how the body processes the drug. It is a first step to see…

This study looked at whether giving palliative radiation to several tumor sites before starting standard immunotherapy and chemotherapy can help people with metastatic non-small cell lung cancer. Fifty adults with cancer that had spread and low PD-L1 levels received radiation to …

This study tested a combination of the immunotherapy drug pembrolizumab with two investigational drugs (MK-4830 or MK-0482) in 102 people with advanced non-small cell lung cancer that had not been treated before and tested positive for a protein called PD-L1. The main goal was to…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…

This Phase 2 study tested the drug lorlatinib in 109 people in China with advanced ALK-positive non-small cell lung cancer whose disease had progressed after treatment with other ALK inhibitors. The goal was to see how many patients' tumors shrank or disappeared. The trial is now…

This study looked at how well the drug Tagrisso (osimertinib) works and how safe it is for people with a certain type of lung cancer (non-small cell lung cancer with EGFR mutations) in everyday medical practice. Over 900 patients in Korea were observed while taking Tagrisso as th…

This early-phase trial tested an experimental drug called TAK-676 combined with the immunotherapy pembrolizumab after radiation therapy in 34 adults with advanced lung, breast, or head/neck cancers that had stopped responding to checkpoint inhibitors. The main goals were to check…

This study looked at 302 patients with advanced non-small cell lung cancer in Greece who were treated with a combination of nivolumab, ipilimumab, and chemotherapy as their first therapy. Researchers tracked patient characteristics, treatment patterns, and survival rates over tim…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…